Branded versus generic clozapine for treatment of schizophrenia

Annals of Pharmacotherapy

Volumn 37, Issue 3, 2003, Pages 350-353

  Makela, Eugene H ^a   Cutlip II, William D ^b   Stevenson, James M ^b   Weimer, Jason M ^b   Abdallah, Ehab S ^a   Akhtar, Raja S ^a   Aboraya, Ahmed S ^b   Gunel, Erdogan ^a   Gonzàlez, Lydia ^c   Vanier, Marie Claude ^c  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Clozapine; Clozaril; Switch

Indexed keywords

CLOZAPINE; GENERIC DRUG;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DETERIORATION; DRUG ABSORPTION; DRUG SAFETY; DRUG SCREENING; DRUG UTILIZATION; FEMALE; FOLLOW UP; HEART ARREST; HUMAN; MALE; OPEN STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOM; TACHYCARDIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 0037369562     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C069     Document Type: Article

References (11)

1. Meyer MC. United States Food and Drug Administration requirements for approval of generic drug products. J Clin Psychiatry 2001;62(suppl 5):4-9.
2. Kluznik JC, Walbek NH, Farnsworth MG, Melstrom K. Clinical effects of a randomized switch of patients from Clozaril to generic clozapine. J Clin Psychiatry 2001;62(suppl 5):145-17.
3. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
4. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-7.
5. Guy W. ECDEU assessment manual for psychopharmacology-revised (DHEW pub. no. ADM-76-338). Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs. 1076:534-7.
6. Ereshefsky L, Richards AL. Psychoses. In: Koda-Kimble MA, Young LY, eds. Applied therapeufics: the clinical use of drugs. Vancouver, WA: Applied Therapeutics, 1992:40-3.
7. Cutler NR. Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients. J Clin Psychiatry 2001;62(suppl 5):10-3.
8. Pokorny R, Finkel MJ, Robinson WT. Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine (letter) Pharm Res 1994;11:1221.
9. Williams RL. Guidance: clozapine tablets in vivo bioequivalence and in vitro dissolution testing. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. November 15, 1996. www.fda.gov/cder/guidance/clozbio.pdf. (accessed 2003 Jan 10).
10. Lam WYF, Ereshefsky L, Toney GB, Gonzales C. Branded versus generic clozapine: bioavailability comparison and interchangeability issues. J Cin Psychiatry 2001;62(suppl 51):18-322.
11. Sajbel TA, Carter GW. Wiley RB. Converting patients from brand-name clozapine to generic clozapine. Ann Pharmacother 2001;35:281-4.